Moreover, the addition of novel biomarkers for AKI diagnosis, such as neutrophil gelatinase-associated lipocalin (NGAL), cycle arrest biomarkers, tissue inhibitor metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein (IGFBP7), may be added in the future to the guidelines to improve AKI diagnosis [30]. This evidence concerns the gene TIMP2 and acute kidney injury.